In patients with R/R NHL, CD19/CD3 and CD20/CD30 BSABs demonstrated better treatment efficacy in indolent FL than in DLBCL (ORR, 66–91% vs. 35–75%) [32, 37–39, 41, 43, 44]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.